{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Furosemide+plus+Chlorothiazide", "query": { "intervention": "Furosemide plus Chlorothiazide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T07:23:41.335Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04467931", "title": "ACEI or ARB and COVID-19 Severity and Mortality in US Veterans", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hypertension", "COVID" ], "interventions": [ { "name": "ACEI/ARB", "type": "DRUG" }, { "name": "Non-ACEI/ARB", "type": "DRUG" }, { "name": "ACEI", "type": "DRUG" }, { "name": "ARB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22213, "start_date": "2020-01-19", "completion_date": "2020-12-31", "has_results": false, "last_update_posted_date": "2021-04-28", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04467931" }, { "nct_id": "NCT00690521", "title": "A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Congestive Heart Failure" ], "interventions": [ { "name": "Treatment of Furosemide + Hydrochlorothiazide", "type": "DRUG" }, { "name": "Treatment of Furosemide + Metolazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "98 Years", "sex": "ALL", "summary": "18 Years to 98 Years" }, "enrollment_count": 8, "start_date": "2004-10-26", "completion_date": "2009-11-10", "has_results": true, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00690521" }, { "nct_id": "NCT01921829", "title": "Protocolized Diuretic Strategy in Cardiorenal Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cardiac Failure", "Renal Failure", "Kidney Failure" ], "interventions": [ { "name": "Protocolized Diuretic Strategy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kelly V. Liang, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "MALE", "summary": "21 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2013-11", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-08-21", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01921829" }, { "nct_id": "NCT01721655", "title": "Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Chronic Lung Disease", "Bronchopulmonary Dysplasia" ], "interventions": [ { "name": "Spironolactone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University Healthcare", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2012-10", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2016-11-30", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721655" }, { "nct_id": "NCT05840536", "title": "Combination Diuretic Therapy for Acute Decompensated Heart Failure", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Decompensated Heart Failure" ], "interventions": [ { "name": "Furosemide plus Chlorothiazide", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ochsner Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2014-05", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2023-05-03", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05840536" }, { "nct_id": "NCT03511118", "title": "Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lactating Women on Select DOI", "Breastfed Infants of Mothers on Select DOI" ], "interventions": [ { "name": "Tranexamic acid (TXA)", "type": "DRUG" }, { "name": "labetalol", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" }, { "name": "nifedipine", "type": "DRUG" }, { "name": "clindamycin", "type": "DRUG" }, { "name": "oxycodone", "type": "DRUG" }, { "name": "azithromycin", "type": "DRUG" }, { "name": "escitalopram", "type": "DRUG" }, { "name": "sertraline", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "Ciprofloxacin", "type": "DRUG" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Levofloxacin", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Sumatriptan", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Cyclobenzaprine", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" }, { "name": "Gabapentin", "type": "DRUG" }, { "name": "Hydrochlorothiazide", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Topiramate", "type": "DRUG" }, { "name": "Trazodone", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Amoxicillin", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Hydrocodone", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1600, "start_date": "2018-10-04", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 20, "location_summary": "La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511118" }, { "nct_id": "NCT00000620", "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Cardiovascular Diseases", "Hypercholesterolemia", "Hypertension", "Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Coronary Disease" ], "interventions": [ { "name": "Anti-hyperglycemic Agents", "type": "DRUG" }, { "name": "Anti-hypertensive Agents", "type": "DRUG" }, { "name": "Blinded fenofibrate or placebo plus simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "40 Years to 79 Years" }, "enrollment_count": 10251, "start_date": "1999-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 6, "location_summary": "Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000620" }, { "nct_id": "NCT02546583", "title": "Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)", "type": "DRUG" }, { "name": "IV Chlorothiazide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 458, "start_date": "2015-08-31", "completion_date": "2020-01-23", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02546583" }, { "nct_id": "NCT05171686", "title": "Diuretics and Volume Overload in Early CKD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Disease", "Hypertension" ], "interventions": [ { "name": "Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2023-02-01", "completion_date": "2025-10-02", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05171686" }, { "nct_id": "NCT00671424", "title": "A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Hydrochlorothiazide (HCTZ)", "type": "DRUG" }, { "name": "Remogliflozin etabonate (GSK189075)", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "18 Years to 50 Years · Male only" }, "enrollment_count": 48, "start_date": "2008-03", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2012-03-19", "last_synced_at": "2026-09-05T07:23:41.335Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671424" } ] }